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Bringing CLARITY to the human brain: visualization of Lewy pathology in three dimensions
Aims: CLARITY is a novel technique which enables
three-dimensional visualization of immunostained tis-
sue for the study of circuitry and spatial interactions
between cells and molecules in the brain. In this study,
we aimed to compare methodological differences in the
application of CLARITY between rodent and large
human post mortem brain samples. In addition, we
aimed to investigate if this technique could be used to
visualize Lewy pathology in a post mortem Parkinson’s
brain. Methods: Rodent and human brain samples were
clarified and immunostained using the passive version
of the CLARITY technique. Samples were then
immersed in different refractive index matching media
before mounting and visualizing under a confocal
microscope. Results: We found that tissue clearing
speed using passive CLARITY differs according to spe-
cies (human vs. rodents), brain region and degree of
fixation (fresh vs. formalin-fixed tissues). Furthermore,
there were advantages to using specific refractive index
matching media. We have applied this technique and
have successfully visualized Lewy body inclusions in
three dimensions within the nucleus basalis of Meynert,
and the spatial relationship between monoaminergic
fibres and Lewy pathologies among nigrostriatal fibres
in the midbrain without the need for physical serial
sectioning of brain tissue. Conclusions: The effective
use of CLARITY on large samples of human tissue
opens up many potential avenues for detailed patholog-
ical and morphological studies.
Keywords: CLARITY, human post mortem brain, Lewy body pathology, three-dimensional visualization, tissue
clearing
Introduction
Interest in studying the brain in fine molecular
detail extends as far back as the 19th century where
Ramon y Cajal adapted the Golgi staining method of
silver impregnation to visualize different classes of neu-
rones. This provided the first evidence to suggest that
neural networks are organized based on connectivity
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and coincided with the early development of light
microscopy [1]. Subsequently, confocal microscopy
with optical sectioning capability has been developed to
allow visualization of thick tissue in high resolution
[2]. This can be used with a combination of fluores-
cently labelled samples for the study of structural con-
nectomics. However, tissue samples have to be cleared
to prevent light scattering from lipids in brain tissues.
The earliest detailed account of tissue clearing was doc-
umented by the German anatomist Werner Spalteholz in
1911, who used wintergreen oil (methyl Salicylate) and
benzyl benzoate to render heart tissue transparent to visu-
alize the vasculature of the heart [3]. The Spalteholz tech-
nique is still used today to visualize deep blood vessels, e.g.
hippocampal vessels [4], but it has the disadvantage of
causing severe tissue damage after long-term incubation
(over 5 months) with various organic solvents. Subse-
quently, the use of benzyl alcohol–benzyl benzoate
(BABB/Murray’s clear) clearing strategy [5,6] and
3DISCO [7,8] (Table 1) were developed from this tech-
nique in combination with fluorescently tagged samples
for the three-dimensional visualization of rodent brain
structures. However, major drawbacks of using organic
solvents in these techniques are the rapid quenching of
fluorescence signals and the incomplete clearance of
heavily myelinated structures. Aqueous-based brain
clearing strategies such as Scale [9], SeeDB [10], ClearT
[11] and CUBIC [12] have been developed (Table 1).
However, other problems such as protein loss, poor trans-
parency, tissue swelling and lack of molecular probing
capability remain an issue.
CLARITY (an acronym for Clear Lipid-exchanged
Acrylamide-hybridized Rigid Imaging/ Immunostaining/
in situ-hybridization-compatible Tissue hYdrogel) is a
novel tissue clearing strategy that aims to overcome the
problems mentioned above, by rendering tissue transpar-
ent whilst preserving its capability for molecular probing
[13]. In brief, this technique uses cross-linking of hydro-
gel monomers and formaldehyde to functional groups on
proteins and nucleic acids. Upon polymerization, a stable
hydrogel-tissue matrix is formed and subsequently, lipids
from the tissue are washed off using sodium dodecyl sul-
phate (SDS) detergent. The resultant hydrogel-tissue com-
plex can then be immunostained and visualized with
confocal or light-sheet microscopy.
The vast majority of the studies involving CLARITY,
including its original description, were designed for
rodent brain tissues. However, the presumed requirement
of a complicated electrophoretic set-up, and the complex-
ity and costly nature of the technique have regrettably
hindered its use in many laboratories. CLARITY has been
applied on human brain tissue [13–15], but so far only
the less myelinated brain tissues of a child [13,15] or thin
500 lm sections [13,14] have been visualized. Further-
more, a protocol applicable for a variety of human brain
tissue types has not yet been optimized. As a result, we set
out to compare methodological differences between
mouse, rat and human brain tissues, using passive
CLARITY tissue clearing as described by Yang et al. [16]
and Tomer et al. [17]. With the potential of CLARITY
being applied on human tissue to aid neuropathological
investigations, such as the 3D visualization of amyloid-
beta plaques in Alzheimer’s brain tissue as reported briefly
in one study [14], we also aimed to demonstrate the util-
ity of CLARITY in pathological investigations of post mor-
tem Parkinson’s disease brain tissues.
Methods
CLARITY hydrogel embedding for rodent brain
tissue
12-week-old C57BL/6 mice and Sprague–Dawley rats
weighing between 250–300 g were terminally anaes-
thetized with sodium pentobarbital (intraperitoneal
injection; 120 mg/kg body weight) and transcardially
perfused with ice-cold phosphate-buffered saline (PBS,
pH7.4) and then with hydrogel monomer solution
consisting of 4% paraformaldehyde (PFA), 2% or 4%
(vol/vol) acrylamide (Bio-Rad, UK), 0.05% (vol/vol)
bis-acrylamide (Bio-Rad, UK), 0.25% (wt/vol) VA-044
photoinitiator (Wako, Alpha-Labs, Eastleigh, UK) and
PBS. Brains were then extracted and immersed in the
same solution for 2 days at 4°C. Next, the brains with
hydrogel solution were transferred into a 50 ml con-
tainer and a layer of olive oil was poured on top of
the solution with the lid tightly screwed to prevent
oxygen inhibition of the subsequent polymerization of
the hydrogel by incubating at 37°C for 3 h (or 4 h
for 2% acrylamide solution). After removal of excess
hydrogel from the hydrogel-tissue hybrid, brain tissues
were left either undissected, bisected into two hemi-
spheres in the case for mouse brains or cut into 3-
mm-thick coronal sections for rat brains using a rat
brain matrix before proceeding to the subsequent clar-
ification step.
© 2015 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society.
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CLARITY hydrogel embedding for human brain
tissue
Human brain tissues from the Parkinson’s UK Tissue
Bank at Imperial College London were used in this
study. Both fresh and formalin-fixed (>4 weeks fixation)
tissues from various brain regions were obtained.
Tissue blocks were cut into 0.5–1-cm-thick and incu-
bated in hydrogel monomer solution as described
above. Fresh brain tissues were incubated for 5–7 days
and formalin-fixed tissues were incubated for 7–
10 days (depending on the block thickness) at 4°C
until a rubbery-firm consistency was reached. The tis-
sue blocks with hydrogel solution were then transferred
into 50 ml containers and a layer of olive oil was
poured on top of the solution, with the lid tightly
screwed on to prevent oxygen inhibition of the subse-
quent polymerization of the hydrogel by incubating at
37°C for 3 h (or 4 h for 2% acrylamide solution). After
removal of excess hydrogel from the hydrogel-tissue
hybrid, tissues were then sectioned into 3 mm blocks
using a scalpel prior to clearing.
Passive tissue clearing
A passive clearing protocol, outlined by Tomer and col-
leagues [17], was adopted in preference to active elec-
trophoretic clearing as described in the original protocol
[13]. Hydrogel-embedded samples were washed with
SDS clearing solution (4% wt/vol SDS in 1 M boric acid
solution, pH8.5; 2 9 24 h at room temperature, RT) to
remove remaining hydrogel monomers. Samples were
then incubated at 50°C in SDS clearing solution to begin
the passive clearing process. Clearing solution was
replaced every 2–3 days. Tissue remained in the clearing
solution until transparency was achieved.
Immunostaining on clarified rodent and human
brain tissues
After clearing, samples were washed thoroughly with
PBS with Triton-X (PBST; 0.1% vol/vol triton-X and
0.01% wt/vol sodium azide in PBS) (2 9 24 h at
37°C) to remove residual SDS micelles. Samples were
incubated with primary antibody in 15 ml containers
with PBST as diluent. Working concentrations for vari-
ous antibodies used are listed in Table 2. Typically,
1 ml of antibody solution is sufficient to cover a 3-mm-T
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thick sample in the container. Tissue samples were
incubated at 37°C for 5 days. Primary antibody was
washed off with PBST (2 9 24 h at 37°C). Secondary
antibody was applied at a concentration of 1:50 and
incubated at 37°C for 5 days. A nuclear counterstain,
40,6-diamidino-2-phenylindole (DAPI; 1:100 from a
stock of 1 lg/ml diluted with 1:1 water: dimethyl
sulphoxide), can be added at this stage. Tissue was
then washed with PBST (2 9 24 h at 37°C) to remove
excess secondary antibody.
Comparison of various refractive index
matching media with human brain tissues
For optimizing tissue refractive index (RI) matching,
roughly 1 9 1 9 1 cm3 of clarified human cerebellum
was each stained in 1:100 dilution of antibodies
against neurofilament in 1 ml of PBST at 37°C for
2 days, followed by washing in excess PBST at 37°C
for 6 h, and stained with secondary antibody at 1:100
dilution in 1 ml of PBST at 37°C for 2 days. After sev-
eral washings, the samples were immersed in 5 ml of
each compared RI matching formula or cleared as
described by various techniques (Table 3).
Imaging
For imaging of immunostained whole or hemisected
mouse brain samples, the CLARITY-treated brain was
incubated in 87% glycerol overnight at room tempera-
ture. For immunostained 3-mm-thick coronal rat brain
or human brain samples, the clarified tissues were
incubated in 87% glycerol or ScaleA2 solution for 3 h
prior to imaging. Samples were mounted in a 50-mm
diameter standard bottom imaging dish (Ibidi, Ger-
many) with a surrounding ring of Blu-Tack to prevent
sample movement. Samples were placed carefully at
the bottom of the dish. RI matching solution was
slowly pipetted to the dish, so as not to agitate the
sample. It was paramount that the sample remained in
contact with the bottom of the dish to ensure the sam-
ple was in focus during imaging, due to the short
working distance of the objective.
Imaging on CLARITY-treated samples was performed
using a Zeiss LSM-780 inverted confocal and Zeiss LSM-
710 upright confocal laser scanning microscopes (Carl
Zeiss, Oberkochen, Germany) either at the Facility for
Imaging by Light Microscopy (FILM) facility in Hammer-
smith Hospital or at the University of Hong Kong Li Ka
Shing Faculty of Medicine Faculty Core Facility. A 920
objective (W Plan Apochromat DIC M27, numerical
aperture 1.0; working distance, 1.7 mm) with laser exci-
tation at 800 nm was used to image the whole mouse
brain tissue. To image various human tissues, a 910
objective (EC Plan-Neofluar, numerical aperture, 0.3;
working distance, 5.2 mm) and 920 objective (Plan
Apochromat DIC, numerical aperture, 0.8; working dis-
tance, 0.55 mm) with laser excitation at 405 nm,
488 nm, 543 nm and 594 nm were used. Image cap-
ture and processing were performed using the Zen Black
Table 2. Antibodies used in the study
Primary antibodies
Catalogue no. Company Host Clonality DilutionAntigen
Neurofilament (NF, 2F11) M0762 Dako Mouse Monoclonal 1:50–1:100
Ionized calcium-binding adapter molecule 1 (IBA1) 019-19741 Wako Rabbit Polyclonal 1:50
a-synuclein (a-syn, 42) 610787 Becton Dickson (BD) Mouse Monoclonal 1:50
Tyrosine hydroxylase (TH) AB152 Millipore Rabbit Polyclonal 1:50–1:100
Secondary antibodies
Catalogue no. Company Host Fluorophore conjugates DilutionName
AlexaFluor anti-goat A-11055 Invitrogen Donkey 488 IgG (H+L) 1:50
AlexaFluor anti-goat A-11057 Invitrogen Donkey 568 IgG (H+L) 1:50
AlexaFluor anti-rabbit A10042 Invitrogen Donkey 568 IgG (H+L) 1:50
AlexaFluor anti-mouse A-21202 Invitrogen Donkey 488 IgG (H+L) 1:50
AlexaFluor anti-rabbit A-11011 Invitrogen Goat 568 IgG (H+L) 1:50
AlexaFluor anti-mouse A-11001 Invitrogen Goat 488 IgG (H+L) 1:50
© 2015 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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(Carl Zeiss, Germany) software. Three-dimensional ren-
dering and video production were performed on Zen
Black (Carl Zeiss, Germany), Volocity (PerkinElmer, MA,
USA) and Fiji (Image J, NIH) software.
For the comparison of fluorescent signal intensity
after immersion in various RI matching solution, a
Leica SP5 inverted confocal microscope with a 910
objective (HC PL APO CS, numerical aperture, 0.40;
working distance 2.2 mm) and laser excitation at
514 nm and 561 nm were used. Image capture was
performed using the Leica Application Suite Advanced
Fluorescence (LAS AF) software. All imaging settings
were the same for each RI-matched sample. Intensity
analysis was done using Fiji macros made by Steve
Rothery which is downloadable in http://www3.
imperial.ac.uk/imagingfacility/resources/macros-n-scripts,
using which intensity profile across the diagonals
through the whole image Z-stacks was analysed, and the
overall maximum intensity was found and compared.
We did not construct a scoring scheme to quantitatively
evaluate each RI matching formula, otherwise many
samples would be required yet inaccurate due to inter-
vening variables. Overall, the description of fluorescent
signal intensity in Table 3 is based on the intensity eval-
uation, our overall impression of the samples under the
microscope, and our experience with different RI match-
ing formulas, which is sufficient as most histological
evaluation focus on morphology rather than quantita-
tive analysis.
Ethical considerations
The work conducted on human tissue was under ethi-
cal approval held by the Parkinson’s UK Brain Bank at
Table 3. Comparison of different refractive index matching solutions
Reagent
Fluorescent
signal
preservation Transparency
Time to maximal
clearance (3 9
3 9 3 mm3
tissue block) Preparation Storage Other remarks
PBST Good + Never Simple Indefinitely N/A
FocusClear Good +++ 2 h (Bought) Cannot be stored Occasional yellow
precipitates or
discoloration observed
87% Glycerol Good ++ Overnight Simple Not recommended,
slight loss of signal
after 2 days
Cheapest and simplest
BABB Poor ++ 3 h Simple but
hazardous
Cannot be stored Over-shrinkage
Histodenz-
RIMS
Moderate in
humans,
good in mice
+++ Overnight Complex Up to 6 months for
mice, up to
1.5 months for
humans
Works best for mice brains
Sorbitol
(sRIMS)
Good +++ Overnight Complex Up to 6 months for
mice, up to
1.5 months for
humans
Take extra care to avoid
fungal growth
SeeDB Moderate ++ 6 h Complex Up to 1.5 months for
humans
Take extra care to avoid
fungal growth
ScaleA2 Good ++++ 3 h Simple Up to 1.5 months for
humans
Tissue remains swollen/
swells even more; most
transparent
THF/DBE Moderate ++ 18 h Simple but
hazardous
Up to 1.5 months for
humans
Over-shrinkage
47% TDE in
PBS
Good ++++ 3 h Simple Up to 1.5 months for
humans
Remains slightly swollen
63% TDE in
PBS
Good +++ 3 h Simple Up to 1.5 months for
humans
Shrinks back to original
size
BABB, benzyl alcohol–benzyl benzoate; DBE, dibenzyl ether; PBS, phosphate-buffered saline; PBST, phosphate-buffered saline with Triton-
X; RIMS, refractive index matching solution; TDE, 2,20-Thiodiethanol; THF, tetrahydrofuran.
© 2015 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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Imperial College London (Registered charity in England
and Wales (258197) and in Scotland (SC037554);
Multicentre Research Ethics Committee approval refer-
ence number: 07/MRE09/72). Parkinson’s UK Brain
Bank is an approved Research Tissue Bank by the
Wales Research Ethics Committee (Ref. No. 08/MRE09/
31+5). Informed consent was obtained prospectively for
the use of post mortem brain tissues and brain samples
were obtained and prepared in accordance to the Wales
Research Ethics Committee approved protocols. All ani-
mal work in this study was performed at the University
of Hong Kong with approval from the Committee on
the Use of Live Animals in Teaching and Research
(CULATR) in the Laboratory Animal Unit (CULATR ref-
erence numbers: 3161-13 and 3494-14), a fully
accredited unit awarded by the Association for Assess-
ment and Accreditation of Laboratory Animal Care
International (AAALAC).
Results
Comparison of passive CLARITY clearing speed
between rodent and human brain tissues
We performed passive CLARITY tissue clearing as
described by Yang et al. [16] and Tomer et al. [17], on
whole mouse and rat brains, and 3-mm-thick sections
on both rat and human brain tissues.
As transcardial perfusion of hydrogel monomer solu-
tion is not possible for human tissue, 0.5–1-cm-thick
brain tissue sections were processed by immersion fixa-
tion in the solution. Long-term formalin-fixed brain tis-
sues took 7–10 days as compared with 5–7 days for
fresh brain tissue to reach a suitable consistency for
subsequent polymerization and clearing steps.
In terms of clearing speed, there was a substantial
difference between rodent and human brain tissues
(Table 4) which may be attributed, at least in part,
to the size of the tissue. A whole mouse brain took
21 days (Figure S1a–c) while a whole rat brain took
approximately 60 days to clear. It is important to
note, however, that complete transparency of rat
brain was not achieved and substantial swelling and
yellowing of tissue were seen. Second, comparing
clearing speed with tissue of the same thickness (3-
mm thick), human tissue took longer than rodent tis-
sues to reach transparency. For cortical tissue,
human tissue took about 3- to 4-times longer than
rodent tissue to clear (Figure 1d–h). As a result, the
total clearing time for a 3-mm-thick human brain
block was approximately 2 months from dissection
(Table 4).
Third, different anatomical regions take differing
amounts of time to clear, apparently dependent on the
degree of myelination. For human tissue, hippocampus
and basal ganglia took the shortest time to clear (7–
10 days), followed by various cortical regions
(~40 days) and brainstem regions caudal to the mid-
brain failed to clear with passive thermal clearing.
Finally, the degree of formalin fixation affects clearing
speed. Fresh human brain cortical tissue processed
directly in passive clearing took about 40 days to clear
which is significantly faster than archival formalin-
fixed cortical tissue which took about 60 days to clear.
The quality of tissue could also be adversely affected
by prolonged passive clearing. Notable tissue swelling
and some degree of tissue yellowing could be observed
for human tissue, perhaps due to residual haemosiderin
deposits or lipofuscin-type pigments present in brain tis-
sue from elderly patients.
We attempted to accelerate the clearing process by
reducing acrylamide concentration from 4% to 2% as
mentioned in a previous report [16] and we found that
rat brain tissue reached transparency faster (5 days as
Table 4. Comparison of tissue clearing speed between rat and human brain tissue blocks (3-mm thick)
Rat Human (fresh) Human (formalin-fixed)
Post-perfusion immersion fixation 2 days 5–7 days 7–10 days
Washing 2 days 2 days 2 days
Passive thermal clearing 5–10 days (cerebral coronal
slices)
~18 days (brainstem)
7–10 days (subcortical blocks)
~40 days (cortical blocks)
~60 days (cortical blocks)
Clearing not achieved for
brainstem
Washing 2 days 2 days 2 days
Total clearing time from dissection ~11–24 days ~15–51 days ~70 days
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compared to 7 days). However, the clearing speed of
the same thickness of human cortical tissue did not
alter and tissue became very fragile and collapsed (Fig-
ure S1i).
Comparison with different refractive index
matching solutions
Refractive index homogenization is an essential step in
the CLARITY protocol before imaging. Several more
cost-effective RI matching solutions have been sug-
gested as an alternative to FocusClear (CelExplorer
Labs, Hsinchu, Taiwan) as described in the original
protocol. We systematically and experimentally evalu-
ated all available RI matching formula available on
clarified mouse and human tissues). In general, for
small tissue with shortest diffusion distance less than
2 mm, 3 h of RI matching at room temperature is suf-
ficient, for larger tissues such as whole mouse brain or
thick slices up to 1 cm in thickness, overnight RI
matching is recommended, and incubation at 37°C
can shorten the process to 4 to 5 h.
Based on the refractive index-matched tissue trans-
parency (Figure S2), fluorescent signal retention (Fig-
ure 1), and other practical aspects (Table 3), we found
that ScaleA2 rendered tissues most transparent, but it
caused substantial tissue swelling.
We then moved on to investigate on 47% 2,20-Thi-
diethanol (TDE), which was the second best in terms
of tissue transparency and it shrunk tissues back to
its original size, however, a slight yellowish discol-
oration remained. By observing the effects of diluting
TDE in PBS, 1.37 M NaCl (normal saline), 10 mM
phosphate buffer (PB), and distilled water on tissue
transparency (Figure S3) and fluorescent signal inten-
sity (Figure S4), we were able to reduce the yellow
discoloration by diluting 47% TDE in PB instead of
the originally proposed PBS, which is recommended
for RI matching in human tissues.
Structural staining of rodent and human tissues
To demonstrate whether the adapted CLARITY tech-
nique is translatable from rodent to human tissues for
molecular probing, we performed structural immunos-
taining using anti-neurofilament (NF) antibodies on
human cortical blocks. A detailed linear pattern of
axon projections through the depth of the tissue, with
neuronal soma was visualized (Figure 2, Video Clip
S1) down to a depth of 771.67 lm. However, a
decrease in fluorescent signals above 500 lm thick-
ness was noted. Monoaminergic neurones were also
visualized with tyrosine hydroxylase (TH) immunos-
taining. Detailed cortical innervation with dense TH-
positive striatal staining was apparent in clarified rat
coronal blocks (Figure 3a) and monoaminergic fibres
in the midbrain were also clearly stained in human
midbrain tissue (Figure 3b).
Figure 1. Human cerebellar cortex stained with anti-neurofilament primary antibody and subsequently AlexaFluor-568-conjugated
donkey anti-mouse secondary antibody and imaged using Leica SP5 confocal microscope with a 109 objective, Z-projections of Z-stacks
500-lm thick (z-stack step size 5 lm), each imaged using the same settings.
© 2015 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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We then investigated spatial relationships between
neurones and glia using double staining with anti-NF
and anti-ionized calcium-binding adapter molecule 1
(IBA1). This revealed the microglial surveillance net-
work surrounding neurones in both mouse and human
tissues (Figure 4).
Figure 2. Immunofluorescence with neurofilament (NF) staining on human cortical tissue. a: A two-dimensional image of NF staining
showing fine axonal processes and neuronal somas. Scale bar = 50 lm. b: Z-stack image of NF immunostaining on a 3-mm block of
human cortex with an imaging depth to 771.67 lm (z-stack step size 5.3 lm).
Figure 3. Z-stack image of Immunofluorescence with tyrosine hydroxylase (TH) staining on rat coronal block showing TH-positive
neuronal processes at the cortex and dense, homogenous staining within the striatum (z-stack step size 3.3 lm) (a). Staining in the
human midbrain block showed dense TH-positive axonal processes (z-stack step size 1.5 lm) (b).
© 2015 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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Pathological investigations in the Parkinson’s
brain with CLARITY
CLARITY has been shown to be useful for pathological
investigations [14]. Staining for alpha-synuclein (aSN)
in the nucleus basalis of Meynert of a Parkinson’s case
revealed characteristic aSN-immunopositive inclusions
that we were able to characterize in three dimensions.
In particular, we identified one characteristic brain-
stem-type Lewy body using this technique, revealing
that a dense, near-spherical shell of aSN forms the
outermost layer of the body as shown in the orthogo-
nal projection image (Figure 5a). This is comparable to
Lewy body inclusions seen using immunofluorescence
on standard 7-lm-thick histological sections (Fig-
ure 5b). We were also able to visualize a Lewy neurite
Figure 4. Double immunofluorescence with anti-neurofilament (a, green) and anti-Iba-1 (b, red) antibodies on human cortical block. c:
Combined figure showing surveillance network of Iba-1-positive microglia around neuronal processes. Scale bar = 50 lm.
Figure 5. An orthogonal projection of a Lewy body-like inclusion in a block of cleared tissue containing the nucleus basalis of Meynert
in human stained with anti-aSN antibody (green), showing a near-spherical aSN shell of the inclusion in the XY, XZ and YZ planes
(Scale bar = 50 lm) (a). A confocal Image of a Lewy body-like inclusion in a standard 7-lm-thick section containing the nucleus basalis
of Meynert stained with single immunofluorescence with anti-aSN antibody (red) and a nuclear counterstain (DAPI, blue) (Scale
bar = 20 lm) (b).
© 2015 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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as well as a pre-Lewy body emerging from the side of
the larger body (Figure 5a, Video Clip S2). Double
immunofluorescence staining with aSN and TH anti-
bodies in the substantia nigra allowed visualization of
aSN-positive inclusions within a dense network of
monoaminergic (TH-positive) fibres. Co-localization of
aSN inclusions with TH-positive fibres was clearly visu-
alized with CLARITY (Figure 6; Video Clip S3),
although not all TH-positive fibres were found to be
immunopositive with aSN as well. In addition, using
anti-TH antibodies with DAPI counterstain revealed
sparse TH-positive fibres within the basal ganglia in a
Parkinson’s case (Figure S5).
Discussion
We have demonstrated the passive CLARITY technique,
without the need for a complicated electrophoretic set-
up, can be helpful in the investigation of pathology in
post mortem Parkinson’s disease brain. Also, the practi-
cal aspects of the passive CLARITY procedure were
compared in detail between mouse, rat and human
brain tissues. In particular, all currently available RI
matching formulations were compared. In addition, the
novel visualization of Lewy bodies in 3D from the
nucleus basalis of Meynert, and the spatial co-
localization of Lewy pathologies in nigrostriatal
monoaminergic fibres highlights the potential of
CLARITY in pathological investigations.
When comparing different tissue clearing strategies,
CLARITY is often regarded as being expensive and
complicated. However, from our work on the rodent
and human tissue, we found that this is not necessarily
the case. Although the original protocol recommended
the use of an electrophoretic set-up, a subsequent
methodology paper [17] actually suggested an
advanced CLARITY protocol with passive thermal
clearing.
High cost of antibody was thought to be a major
concern. However, after a detailed cost analysis with
various primary and secondary antibodies used in this
study, it was shown this cost was not significant even
with the use of maximum concentration as suggested
in the original CLARITY protocol (1:50 dilution). In
fact, for the same thickness of tissue, the use of tradi-
tional serial sectioning through the entire tissue block
would potentially consume a greater amount of anti-
bodies. Assuming sections are cut at 10-lm thick, this
would yield 300 sections for a 3-mm-thick block. Using
an optimized dilution for immunohistochemistry on tis-
sue sections, this could cost up to two- to three-times
more than CLARITY-treated tissue blocks.
The use of SDS in CLARITY has been criticized for its
potential for causing damage to the tissue. However,
we did not observe any significant structural or mor-
phological differences after tissue clearing in either
rodent or human tissue. Deisseroth’s group has demon-
strated protein loss with CLARITY at 8% as compared
to 65% when a hydrogel-tissue hybrid was not used for
tissue clearing [13]. For a 2-mm-thick tissue cube, we
found a comparable 13% protein loss in human brain
clearing (unpublished observation). This indicates the
possibility of the formation of a hydrogel matrix which
may help protect the tissue from damage by SDS. Fur-
thermore, SDS has been traditionally used as an anti-
gen retrieval agent for immunohistochemistry, hence,
the use of SDS in tissue clearing could be beneficial
in aiding exposure of several antigens for molecular
tagging.
An essential step of CLARITY is RI matching. Accord-
ing to Chung and colleagues (2013), FocusClear
works best as its RI matches that of the hydrogel-tissue
matrix (~1.45). However, the use of this commercially
available but expensive reagent was frequently cited to
be a prohibitive factor for this technique. We and
others have found the use of FocusClear unnecessary
and 47% TDE was a more cost-effective option for
Figure 6. Z-stack image of double immunofluorescence with anti-
aSN (green) and anti-TH (red) antibodies on human midbrain
block (z-stack step size 1.5 lm).
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human brain tissues. In our hands, in terms of optical
transparency and best preservation of fluorescent sig-
nals, Histodenz-RI matching solution (RIMS) worked
well in transgenic mouse tissues but not for human
ones, which highlights the differences between human
and mouse tissues. However, the principles behind this
phenomenon remained to be explored. We observed
that the amount of yellow discoloration in RI-matched
tissues roughly correlates with the amount of shrink-
age, which in turn depends on the osmotic strength of
the RI matching solution. We tested this idea by dilut-
ing TDE in PB, instead of the original formulation using
PBS, for RI matching. Indeed, removing the saline com-
ponent of PBS reduces yellow discolorations and
improves transparency (Figure S3); RI matching with
47% TDE in water results in remarkable transparency,
but also greatly reduces fluorescence intensity (Fig-
ure S4), presumably due to pH fluctuations as the fluo-
rescent dyes are pH-sensitive. As yellow discoloration
can be prominent in large human tissue samples, our
observation and deduction should prompt future devel-
opment of a better buffering agent with lower osmotic
strength.
Currently, there are only three published reports
involving CLARITY on human brain tissues (Table 5)
[13–15] and in each study the tissue was cleared and
visualized with slightly different conditions. The origi-
nal method paper processed 500 lm blocks of tissue
from a 7-year-old autistic patient, showing the 3D ren-
dering of neuronal projections, as well as a specialized,
atypical laddering pattern of neurones, characteristic of
neurones from animals with autism-like behaviour
[13]. 500-lm-thick brain samples from Alzheimer’s
disease patients, immunostained for tau and amyloid-
beta, revealed the 3D structures of plaques and tangles
and the interaction between the two pathologies. In
addition, this group tried other clearing techniques
(Scale, SeeDB, 3DISCO), but found that CLARITY gave
the best results [14]. Most recently, sections from a
patient with hemimegalencephaly have been CLARITY-
processed, allowing for three-dimensional tracing
of GABA-ergic interneurones in a 2-mm section of
tissue [15].
We expanded on these studies by clarifying different
regions of the brain in addition to cortical blocks.
Although the clearing speed for our samples were
slightly longer (7–60 days) than that in other studies
(1–14 days), this could be due to the thicker samples Ta
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we used for CLARITY (3 mm vs. 0.5- to 2-mm-thick
tissues) and the more heavily myelinated tissue from
elderly patients we used compared with children’s brain
[13,15]. Furthermore, we have shown that the
CLARITY technique can be used with unfixed as well
as formalin-fixed human brain tissue.
Interestingly, none of the studies involving the
human brain, including this study, was successful in
imaging cleared tissues beyond 1 mm in depth. Imag-
ing depth of CLARITY appears to be limited by several
factors. First, as mentioned above, different RI match-
ing reagent has varying effect on optical transparency
and preservation of fluorescence signal. Currently avail-
able reagents may still not be optimal. Second, optical
properties of the objectives of microscopes, in particular
the working distance, is a physical restraint to the size
of the piece of tissue able to be processed with
CLARITY. However, some of the long-working distance
objectives nowadays can image tissue up to 12 mm in
depth. Third, the depth of penetration of antibodies is
perhaps the biggest limitation currently. Although the
exact physical diffusion limit of antibodies is yet to be
determined, it appeared that some antibodies (e.g. anti-
TH) could penetrate a greater depth than others target-
ing antigens which are more abundantly expressed
(e.g. IBA-1). We hypothesize this is due to “overcrowd-
ing” of antibodies at the surface for densely expressed
antigens which prevents further penetration into the
tissue. Further work is therefore needed to identify the
practical limit and optimal parameters (including dilu-
tion factor and incubation times) for antibody penetra-
tion targeting different antigens to allow thorough
investigation of large anatomical structures in the
human brain.
Even though CLARITY cannot yet be used on a large
human brain blocks for connectomic studies, spatial
interaction between different proteins could be clearly
visualized. In this study, we presented the spatial co-
localization of Lewy pathology and monoaminergic
(TH-positive) fibres in the midbrain of a post mortem
human brain. This study is the first to visualize the
three-dimensional structure of a Lewy body, supple-
menting findings from a previous study [18] which
gathered this information by serial sectioning and com-
puterized reconstruction of brain tissue. Using
CLARITY, we validated that a Lewy body is composed
of a spherical or near-spherical aSN shell simply with
optical sectioning with confocal microscopy.
CLARITY is a powerful technique with great poten-
tial, not only for neuroscience research as it is also
applicable for other tissue types [19]. However, this
technique is still in its infancy and some inherent limi-
tations remain. For example the possibility of antigen
re-probing was described in the original protocol [13]
but so far there have been no further reports confirm-
ing the success of this approach. We attempted this on
human brain tissue but some residual fluorescent sig-
nals were present (unpublished observation). In addi-
tion, tissue swelling after active or passive clearing in
CLARITY was reported to be transient. This has yet to
be validated as certain morphological and structural
changes, e.g. breaking of blood–brain barrier integrity,
could be produced artificially. In addition, even though
CLARITY has great molecular probing capacity, anti-
bodies which normally require complicated antigen
retrieval procedures might still pose compatibility issues
with CLARITY.
Nevertheless, the CLARITY technique is constantly
evolving and since its first description, several groups
have improved on the “active” electrophoretic tissue
clearing, including the use of 3D printing of a CLARITY
electrophoretic clearing chamber [20], optimization of
active clearing on various tissue organ [19] as well as
the use of the electrophoretic apparatus to aid penetra-
tion of antibodies to visualize deeper into the tissue
[21]. To improve the passive clearing procedure, thick-
ness of the tissue [22] and the composition of the
hydrogel monomer cocktail has been altered [16,23].
In addition, the introduction of CLARITY-optimized
optics as well as light sheet microscopy technique [17]
will hopefully further increase the utility of this tech-
nique. Our future work will include the full optimiza-
tion of the CLARITY protocol for the use on human
brain tissue as this technique has limitless potential in
contributing to our understanding of human neurologi-
cal conditions.
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Supporting information
Additional Supporting Information may be found in the
online version of this article at the publisher’s web-site:
Figure S1. Comparison of clearing speed between differ-
ent tissues. a–c: Clearing of a whole mouse brain to
transparency in 21 days. d–f: Clearing of a 3-mm block
of rat brain to transparency in 10 days. g, h: Clearing
of a 3-mm block of human cortical tissue to trans-
parency in 39 days. i: human brain tissue cross-linked
with 2% instead of 4% acrylamide does not improve
clearing speed. Tissue integrity is also considerably
worse than that with 4% acrylamide.
Figure S2. 1 9 1 9 1 cm3 of human cerebellum
stained with anti-neurofilament and refractive index-
matched for 28 h at room temperature in different for-
mula/techniques, upper row from left to right: Focu-
sClear, 87% Glycerol, Histodenz-RIMS, Sorbitol
(sRIMS), ScaleA2, SeeDB, PBST (control), 47% TDE in
water, 63% TDE in water, 47% TDE in PBS, 63% TDE
in PBS; lower left: clearing by dehydration (methanol
series)-BABB method; lower right: clearing by dehydra-
tion (THF series)-DBE method.
Figure S3. 1 9 1 9 1 cm3 of human cerebellum
stained with anti-neurofilament and RI-matched for
28 h at room temperature in 47% TDE with different
diluents, from left to right: in PBS, in 1.37 M NaCl, in
10 mM phosphate buffer, in water.
Figure S4. Z-projections of samples in Figure S3 RI-
matched in 47% TDE diluted in different medium. From
left to right: in PBS, in 1.37 M NaCl, in 10 mM phos-
phate buffer, in water.
Figure S5. A 3 9 3 tiled Z-projection (z-stack
depth = 419.95 lm, step size = 2.295 lm) of a basal
ganglia section stained using anti-TH antibody with a
nuclear counterstain 40,6-diamidino-2-phenylindole
(DAPI), revealing the sparse monoaminergic fibres in a
Parkinson’s case. Scale bar = 80 lm.
Video Clip S1. Three-dimensional visualization of neu-
rofilament immunohistochemical staining in post mor-
tem human cortical tissue. A 3-mm block of human
cortex was immunostained using anti-neurofilament
antibody (green). Stained tissue was visualized using a
109 objective (EC Plan-Neofluar, numerical aperture,
0.3; working distance, 5.2 mm) with an imaging depth
to 771.67 lm (z-stack step size 5.3 lm).
Video Clip S2. Three-dimensional visualization of a
Lewy body in the human nucleus basalis of Meynert. A
3-mm block of human nucleus basalis of Meynert was
immunostained using anti-alpha-synuclein antibody
(green). Stained tissue was visualized using a 209
objective (Plan Apochromat DIC, numerical aperture,
0.8; working distance, 0.55 mm; z-stack step size
1.1 lm).
Video Clip S3. Three-dimensional visualization of
monoaminergic fibres and Lewy pathologies in the post
mortem human midbrain tissue. A 3-mm block of
human midbrain tissue was immunostained using anti-
alpha-synuclein antibody (green) and tyrosine hydroxy-
lase (red). Stained tissue was visualized using a 209
objective (Plan Apochromat DIC, numerical aperture,
0.8; working distance, 0.55 mm) with an imaging
depth to 312.62 lm (z-stack step size 1.5 lm).
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